There are 2789 resources available
699P - Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)
Presenter: Jonathan Rosenberg
Session: ePoster Display
700P - Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC)
Presenter: Yohann Loriot
Session: ePoster Display
701P - Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) Tx: Results from IMPACT UC
Presenter: Mehmet Bilen
Session: ePoster Display
703P - Camrelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
Presenter: Nianzeng Xing
Session: ePoster Display
704P - Treatment patterns among patients with advanced urothelial carcinoma (aUC) in the USA
Presenter: Alicia Morgans
Session: ePoster Display
705P - Systematic literature review (SLR) and network meta-analysis (NMA) of first-line (1L) therapies for locally advanced/metastatic urothelial carcinoma (la/mUC)
Presenter: Lisa Bloudek
Session: ePoster Display
706P - Real-world study assessing physician rationale for initiating first-line (1L) immuno-oncology (IO) therapy for patients with advanced urothelial cancer (aUC)
Presenter: Mayank Ajmera
Session: ePoster Display
867P - A phase I trial of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma
Presenter: Ari Rosenberg
Session: ePoster Display